Daiichi acquiring Plexxikon for $805M in cash, plus up to $130M in milestones related to the approval of Plexxikon's melanoma candidate PLX4032 (RG7204)

Plexxikon Inc.

U.S. / Private Biopharma

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Daiichi Sankyo Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Completed

Sample

01/01/2009

announced

01/01/2009

completed